Tesofensine for weight loss: what the trials actually show

What did @andimay77 actually say?

After a late Super Bowl night, the creator credits a "little wonderful capsule" of what she calls "Tessa Fensine" with eliminating her brain fog, restoring mental clarity, and giving her a full day of energy. She also claims tesofensine "helps aid in increased weight loss" whether taken alone or alongside GLP-1 medications, and directs viewers to a telehealth website for more information.

Two distinct claims are being made here. First, that tesofensine functions as a reliable cognitive and energy booster. Second, that it amplifies weight loss when stacked with GLP-1 drugs like semaglutide or tirzepatide. Neither of those claims comes with a disclaimer, a prescription context, or any mention of side effects. That matters a lot for a compound that works on the central nervous system.

Does the science back this up?

Tesofensine does have real weight loss data behind it, but the cognitive and energy claims are almost entirely unsupported by published human evidence. Let's be precise about what we know.

On weight: a Phase 2 randomized controlled trial by Astrup et al. (2008, The Lancet) showed tesofensine at 0.5 mg daily produced roughly 10.6% body weight loss over 24 weeks, outperforming placebo significantly. That is a real signal. The drug inhibits reuptake of serotonin, dopamine, and norepinephrine, which suppresses appetite and increases energy expenditure.

On cognition and energy: the norepinephrine and dopamine reuptake inhibition could plausibly produce a stimulant-like effect, but no published clinical trial has established tesofensine as a brain fog treatment or a cognitive enhancer. The creator is extrapolating from its mechanism, not citing evidence. That is a meaningful distinction. The same mechanism also raises cardiovascular concerns, including elevated heart rate and blood pressure, documented in the Astrup trial.

On GLP-1 stacking: there is no published human RCT data on combining tesofensine with semaglutide or tirzepatide. The additive weight loss claim is speculative.

What did they get wrong (or right)?

Credit where it is due: tesofensine is not snake oil. The weight loss data from Astrup et al. is legitimate, and interest in it as an adjunct obesity therapy is real. NeuroSearch advanced it into Phase 3 consideration. The creator is not inventing a compound.

What she got wrong is more serious, though. Framing a triple monoamine reuptake inhibitor as a casual morning capsule for energy and mental clarity, with zero mention of cardiovascular risks, is irresponsible. The Astrup trial noted increased heart rate and dry mouth as frequent adverse effects. Tesofensine structurally resembles stimulant-class compounds. Presenting it the way you would present a cup of coffee is misleading.

The "take it in conjunction with your GLP-1 medications" line is the most problematic moment. Stacking a norepinephrine-dopamine-serotonin reuptake inhibitor on top of a GLP-1 agonist without clinical supervision, individualized dosing assessment, and cardiac monitoring is not something a social media video should be casually encouraging. No safety data exists for that combination in published literature.

What should you actually know?

Tesofensine is not FDA-approved for any indication as of 2025. In the United States, it is available through compounding pharmacies as an investigational or off-label compound, which means formulations, dosing, and purity are not standardized the way they are for approved drugs. That is not automatically disqualifying, but it means the consumer burden of due diligence is higher, not lower.

If you are interested in tesofensine after seeing content like this, the right next step is a conversation with a licensed prescriber who can review your cardiovascular history, your current medications including any GLP-1 drugs, and your individual risk profile. The weight loss mechanism is real. The cognitive enhancement pitch is not supported. And the casual "message us today" call to action at the end of a hype video is not a substitute for a clinical intake.

Anyone already on semaglutide or tirzepatide should not add tesofensine based on a TikTok. The combination is understudied and carries theoretical risks that have not been evaluated in a controlled setting.